Scarica l'app Stockscreener
8.21
2.15%
-0.18
Precedente Chiudi:
$8.39
Aprire:
$8.45
Volume 24 ore:
705.45K
Relative Volume:
0.48
Capitalizzazione di mercato:
$729.08M
Reddito:
$73.48M
Utile/perdita netta:
$-108.30M
Rapporto P/E:
-3.6489
EPS:
-2.25
Flusso di cassa netto:
$-67.17M
1 W Prestazione:
+1.92%
1M Prestazione:
-6.49%
6M Prestazione:
+69.98%
1 anno Prestazione:
+64.53%
Intervallo 1D:
$8.12
$8.76
Intervallo di 1 settimana:
$7.67
$9.0364
Portata 52W:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Nome
Personalis Inc
Settore
Industria
Telefono
650-752-1300
Indirizzo
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.21 | 745.07M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Iniziato | Guggenheim | Buy |
| 2025-03-17 | Iniziato | Craig Hallum | Buy |
| 2023-02-06 | Aggiornamento | Needham | Hold → Buy |
| 2022-01-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Downgrade | Needham | Buy → Hold |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-20 | Reiterato | Needham | Buy |
| 2021-05-06 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2021-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-12 | Reiterato | Needham | Buy |
| 2020-11-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-08-27 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2019-09-26 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Iniziato | BofA/Merrill | Neutral |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Morgan Stanley | Overweight |
| 2019-07-15 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Personalis Inc Borsa (PSNL) Ultime notizie
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Mood: Is Personalis Inc showing insider buyingTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Aug Patterns: Will Personalis Inc outperform small cap indexesJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Why Personalis Inc. stock could benefit from AI revolutionWeekly Earnings Recap & Consistent Growth Equity Picks - mfd.ru
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Personalis Data Breach Potentially Exposes PII and PHI - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis (NASDAQ:PSNL) Price Target Raised to $13.00 - MarketBeat
Medicare approves Personalis’ lung cancer test for surveillance By Investing.com - Investing.com Canada
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Investment Magazine
Personalis (PSNL) Gains 10% Following Medicare Coverage for Canc - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap UpShould You Buy? - MarketBeat
Personalis wins Medicare coverage for NeXT Personal (PSNL) - Seeking Alpha
Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com - Investing.com India
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Asianet Newsable
Personalis rises as Medicare extends coverage to lung cancer test - TradingView
Personalis Inc receives Medicare coverage for Next Personal in lung cancer surveillance - marketscreener.com
Medicare approves Personalis’ lung cancer test for surveillance - Investing.com
Personalis Inc Receives Medicare Coverage For Next Personal In Lung Cancer Surveillance - TradingView
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
Revenue Check: Can Personalis Inc stock double in the next yearJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL - MarketBeat
Breakthrough Cancer Monitoring Technique Fuels Growth for Personalis - AD HOC NEWS
Aug Final Week: Is Personalis Inc showing insider buyingLong Setup & AI Enhanced Trading Signals - baoquankhu1.vn
Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance
Personalis (PSNL) Study Highlights NeXT Personal's Impact in Can - GuruFocus
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - MarketBeat
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | PSNL Stock News - GuruFocus
Gainers Report: Is Personalis Incs growth already priced inShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy? - Defense World
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares - Investing.com Nigeria
Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares By Investing.com - Investing.com Australia
Personalis (NASDAQ:PSNL) Reaches New 12-Month HighWhat's Next? - MarketBeat
Personalis Sees Revised Reimbursement Rates for Cancer Tests - MSN
Personalis (NASDAQ:PSNL) Trading 14.8% HigherStill a Buy? - MarketBeat
Aug Swings: Can Personalis Inc stock double in the next yearJuly 2025 Sector Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Market Rankings: How does PLRX perform in inflationary periodsWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance
Winners Losers: Is Personalis Incs growth already priced inDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Personalis Inc Azioni (PSNL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):